FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:631-634 August 29, 1996 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Fulminant hepatic failure is a dramatic clinical syndrome characterized by massive necrosis of liver cells.¹ It is most often caused by hepatitis A virus and hepatitis B virus (HBV)²; whether hepatitis C virus (HCV) can cause it is still controversial.^3,4 Among patients with non-A, non-B fulminant hepatitis, antibodies against HCV (anti-HCV) or serum HCV RNA were found in 40 to 60 percent in Japan^5,6 and Taiwan,⁷ but in only 2 percent (range, 0 to 12 percent) in Western countries,^{8,9,10,11,12,13} with one exception: a recent study conducted in California reported a prevalence of 60 percent associated with low socioeconomic status . . . [Full Text of this Article]

Case Report

Methods

Anti-HCV Testing

Detection, Titration, Genotyping, and Sequencing of HCV RNA

Detection of Serum HGV RNA

Detection of Serum HBV DNA

Liver-Biopsy Studies and Immunohistochemical Staining for the Detection of HCV Antigen in the Liver

Results

Discussion

Source Information

From the Hepatitis Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (P.F., A.S., R.H.P.), and the Department of Transfusion Medicine, Warren G. Magnuson Clinical Center (H.J.A., L.C.C., J.C.M., J.W.S.), National Institutes of Health, Bethesda, Md.; the Department of Pathology, Rancho Los Amigos Medical Center, Downey, Calif. (S.G.); and the Division of Clinical and Laboratory Service, Georgetown Medical Center, Washington, D.C. (R.A.S.).

Address reprint requests to Dr. Farci at the Istituto di Medicina Interna, University of Cagliari, Via San Giorgio 12, 09124 Cagliari, Italy.

References

This article has been cited by other articles:

• Ciocca, M, Ramonet, M, Cuarterolo, M, Lopez, S, Cernadas, C, Alvarez, F (2008). Prognostic factors in paediatric acute liver failure. Arch. Dis. Child. 93: 48-51 [Abstract] [Full Text]  
• Selin, L. K., Brehm, M. A. (2007). Frontiers in Nephrology: Heterologous Immunity, T Cell Cross-Reactivity, and Alloreactivity. J. Am. Soc. Nephrol. 18: 2268-2277 [Abstract] [Full Text]  
• Sakai, A., Takikawa, S., Thimme, R., Meunier, J.-C., Spangenberg, H. C., Govindarajan, S., Farci, P., Emerson, S. U., Chisari, F. V., Purcell, R. H., Bukh, J. (2007). In Vivo Study of the HC-TN Strain of Hepatitis C Virus Recovered from a Patient with Fulminant Hepatitis: RNA Transcripts of a Molecular Clone (pHC-TN) Are Infectious in Chimpanzees but Not in Huh7.5 Cells. J. Virol. 81: 7208-7219 [Abstract] [Full Text]  
• Farci, P., Quinti, I., Farci, S., Alter, H. J., Strazzera, R., Palomba, E., Coiana, A., Cao, D., Casadei, A. M., Ledda, R., Iorio, R., Vegnente, A., Diaz, G., Tovo, P.-A. (2006). Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc. Natl. Acad. Sci. USA 103: 8475-8480 [Abstract] [Full Text]  
• Yu, M.-L., Hou, N.-J., Dai, C.-Y., Chang, W.-Y., Chuang, W.-L. (2005). Successful Treatment of Fulminant Hepatitis C by Therapy with Alpha Interferon and Ribavirin. Antimicrob. Agents Chemother. 49: 3986-3987 [Full Text]  
• Rehermann, B., Shin, E.-C. (2005). Private aspects of heterologous immunity. JEM 201: 667-670 [Abstract] [Full Text]  
• Urbani, S., Amadei, B., Fisicaro, P., Pilli, M., Missale, G., Bertoletti, A., Ferrari, C. (2005). Heterologous T cell immunity in severe hepatitis C virus infection. JEM 201: 675-680 [Abstract] [Full Text]  
• Harvey, C. E., Post, J. J., Palladinetti, P., Freeman, A. J., Ffrench, R. A., Kumar, R. K., Marinos, G., Lloyd, A. R. (2003). Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J. Leukoc. Biol. 74: 360-369 [Abstract] [Full Text]  
• Sulkowski, M. S., Ray, S. C., Thomas, D. L. (2002). Needlestick Transmission of Hepatitis C. JAMA 287: 2406-2413 [Abstract] [Full Text]  
• Lauer, G. M., Walker, B. D. (2001). Hepatitis C Virus Infection. NEJM 345: 41-52 [Full Text]  
• Luppi, M., Barozzi, P., Schulz, T. F., Setti, G., Staskus, K., Trovato, R., Narni, F., Donelli, A., Maiorana, A., Marasca, R., Sandrini, S., Torelli, G., Sheldon, J. (2000). Bone Marrow Failure Associated with Human Herpesvirus 8 Infection after Transplantation. NEJM 343: 1378-1385 [Abstract] [Full Text]  
• Ben-Ari, Z., Samuel, D., Zemel, R., Baruch, Y., Gigou, M., Sikuler, E., Tur-Kaspa, R. (2000). Fulminant Non-A-G Viral Hepatitis Leading to Liver Transplantation. Arch Intern Med 160: 388-392 [Abstract] [Full Text]  
• LAU, G. K K, WILLIAMS, R. (1999). HCV in hepatic failure: West and East do not meet. Gut 45: 481-482 [Full Text]  
• Munoz, S. J., Alter, H. J., Nakatsuji, Y., Shih, J. W.-K., Reddy, R. K., Jeffers, L., Schiff, E. R., Reid, A. E., Marrone, A., Rothstein, K., Manzarbeitia, C., Liang, T. J. (1999). The Significance of Hepatitis G Virus in Serum of Patients With Sporadic Fulminant and Subfulminant Hepatitis of Unknown Etiology. Blood 94: 1460-1464 [Abstract] [Full Text]  
• Worman, H. J. (1997). Molecular biological methods in diagnosis and treatment of liver diseases. Clin. Chem. 43: 1476-1486 [Abstract] [Full Text]